skip to main content

United Therapeutics Corporation to Announce Fourth Quarter and Annual 2011 Financial Results Before Market Open on Tuesday, February 14, 2012

SILVER SPRING, Md., Feb. 7, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2011 financial results before market open on Tuesday, February 14, 2012.

United Therapeutics will host a half-hour teleconference on Tuesday, February 14, 2012, at 9:00 a.m. Eastern Time.  The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using conference code: 46781201.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.  [uthr-g]

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

SOURCE United Therapeutics Corporation

Recent Press Releases

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond,Chief Financial Officer and Treasurer, will provide a company...
The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF) preserved lung function as measured by absolute forced vital capacity (FVC) and...
The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening in predominantly pre-treated patients with...
First-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDASILVER SPRING, Md. & RESEARCH TRIANGLE PARK...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond,Chief Financial Officer and Treasurer, will provide a company...
Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) include efficacy and safety results from TETON-1 and integrated results from TETON-1...